Antibiotic resistance test for gonorrhea gets FDA breakthrough nod

  15 June 2019

FDA granted a breakthrough designation to Australia-based SpeeDx to expedite the path to U.S. clearance for a molecular test that detects both N. gonorrhea and a patient’s susceptibility or resistance to the antibiotic ciprofloxacin.

Results from the ResistancePlus GC test can be used to determine whether patients can be treated with ciprofloxacin rather than ceftriaxone, the current front-line treatment for gonorrhea.

There have been reports in the United Kingdom and Australia of resistance to ceftriaxone, an antibiotic used to treat many kinds of bacterial infections, including organisms that are resistant to other antibiotics.

Further reading: MedTechDive
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!